As a potential platform drug and the Company’s lead therapeutic, ANAVEX 2-73 targets misfolded proteins central to many neurodegenerative diseases, including Parkinson’s and Alzheimer’s. It is believed to enhance the body's own cellular defense mechanisms through both sigma-1 and muscarinic receptors to return diseased cells to a pre-diseased or “homeostatic” state.
“The development of disease-modifying therapies for Parkinson’s disease is the top priority of The Michael J. Fox Foundation and ANAVEX 2-73 presents a promising approach,” said Marco Baptista, PhD, Senior Associate Director of MJFF Research Programs. “Companies that receive funding from MJFF have scientifically compelling plans that hold obvious potential to impact our understanding of Parkinson’s and ultimately the development of improved treatments for people with the disease. To that end, we look forward to the results of the ANAVEX 2-73 study.”
On August 12, 2015, Anavex announced that it has received a Notice of Allowance from the U.S.
Patent and Trademark Office for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon
issuance, the patent will provide intellectual property protection until at least 2030. The
allowed patent claims cover formulations and treatments that provide particular coverage relating
to improved sigma receptor ligands and their use.
regarding Phase 3 trials. I am holding tight.
Low Market CAP continues,